Related Experiment Video
Updated: Jun 1, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Immune thrombocytopenia: no longer 'idiopathic'
1Department of Hematologic Oncology and Blood Disorders, Taussig CancerInstitute, Cleveland Clinic, Cleveland, OH 44195, USA. mccraek@ccf.org
Abstract:
Immune thrombocytopenia (ITP) is a common hematologic disorder. Its pathogenesis involves both accelerated platelet destruction and impaired platelet production. First-line agents are usually effective initially but do not provide long-term responses. Splenectomy remains an effective long-term therapy, as does rituximab (Rituxan) in a subset of patients. Thrombopoietic agents offer a new alternative, although their place in the overall management of ITP remains uncertain.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Endocarditis II: Clinical Features of Infective Endocarditis
Myocarditis II: Clinical Features and Diagnostic Tests
Drug toxicity: Idiosyncratic Reactions

